Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Colorectal Neoplasms

Advanced Liver Cancers

Chordoma, Sarcoma, Rhabdoid Tumor

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Urothelial Cancer

Rectal Neoplasms

Esophageal Squamous Cell Carcinoma

Advanced Solid Malignancies

Esophageal Neoplasms

Small Cell Lung Carcinoma

Endometrial Neoplasms

Lung Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Small Cell Lung Carcinoma

PD-L1-selected Solid Tumors

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Esophageal Neoplasms

Carcinoma, Hepatocellular

Advanced Rare Malignant Solid Neoplasm

Pancreatic Adenocarcinoma

Spinocerebellar Degenerations, Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Head and Neck Neoplasms, Melanoma

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

Advanced Unresectable or Metastatic Solid Malignancy

Glioblastoma

Solid Tumors

Neoplasm Metastasis

Solid Tumor, Adult

Stomach Neoplasms

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Clinical Trials

SKYSCRAPER-03

SKYSCRAPER-06

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

MORPHEUS-LIVER

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Morpheus Lung

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

UmbrellaMAX

SKYSCRAPER-09

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

SKYSCRAPER-07

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

SKYSCRAPER-08

SKYSCRAPER-02

EndoMAP

INDIGO

SKYSCRAPER-04

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

SKYSCRAPER-02C

SKYSCRAPER-11

SKYSCRAPER-15

SKYSCRAPER-01

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

SKYSCRAPER-14

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

TIRACAN

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

MyTACTIC

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

IMperator

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

MoST-TAP

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma